nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Keratopathy—Vandetanib—thyroid cancer	0.145	0.145	CcSEcCtD
Apraclonidine—Visual acuity reduced—Vandetanib—thyroid cancer	0.0331	0.0331	CcSEcCtD
Apraclonidine—Dry eye—Vandetanib—thyroid cancer	0.0182	0.0182	CcSEcCtD
Apraclonidine—Rhinorrhoea—Sorafenib—thyroid cancer	0.0164	0.0164	CcSEcCtD
Apraclonidine—Nasopharyngitis—Vandetanib—thyroid cancer	0.0128	0.0128	CcSEcCtD
Apraclonidine—Infestation NOS—Vandetanib—thyroid cancer	0.011	0.011	CcSEcCtD
Apraclonidine—Infestation—Vandetanib—thyroid cancer	0.011	0.011	CcSEcCtD
Apraclonidine—Conjunctivitis—Vandetanib—thyroid cancer	0.0107	0.0107	CcSEcCtD
Apraclonidine—Bradycardia—Vandetanib—thyroid cancer	0.0101	0.0101	CcSEcCtD
Apraclonidine—Haemorrhage—Vandetanib—thyroid cancer	0.00988	0.00988	CcSEcCtD
Apraclonidine—Visual impairment—Vandetanib—thyroid cancer	0.00952	0.00952	CcSEcCtD
Apraclonidine—Eye disorder—Vandetanib—thyroid cancer	0.00924	0.00924	CcSEcCtD
Apraclonidine—Angiopathy—Vandetanib—thyroid cancer	0.00897	0.00897	CcSEcCtD
Apraclonidine—Mediastinal disorder—Vandetanib—thyroid cancer	0.00891	0.00891	CcSEcCtD
Apraclonidine—Arrhythmia—Vandetanib—thyroid cancer	0.00883	0.00883	CcSEcCtD
Apraclonidine—Mental disorder—Vandetanib—thyroid cancer	0.00866	0.00866	CcSEcCtD
Apraclonidine—Nasopharyngitis—Sorafenib—thyroid cancer	0.00862	0.00862	CcSEcCtD
Apraclonidine—Dysgeusia—Vandetanib—thyroid cancer	0.00843	0.00843	CcSEcCtD
Apraclonidine—Lacrimation—Epirubicin—thyroid cancer	0.00834	0.00834	CcSEcCtD
Apraclonidine—Vision blurred—Vandetanib—thyroid cancer	0.00811	0.00811	CcSEcCtD
Apraclonidine—Abdominal discomfort—Sorafenib—thyroid cancer	0.00799	0.00799	CcSEcCtD
Apraclonidine—Lacrimation—Doxorubicin—thyroid cancer	0.00772	0.00772	CcSEcCtD
Apraclonidine—Keratitis—Epirubicin—thyroid cancer	0.00757	0.00757	CcSEcCtD
Apraclonidine—Parosmia—Epirubicin—thyroid cancer	0.00757	0.00757	CcSEcCtD
Apraclonidine—Infestation NOS—Sorafenib—thyroid cancer	0.00743	0.00743	CcSEcCtD
Apraclonidine—Infestation—Sorafenib—thyroid cancer	0.00743	0.00743	CcSEcCtD
Apraclonidine—Chest pain—Vandetanib—thyroid cancer	0.00732	0.00732	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00727	0.00727	CcSEcCtD
Apraclonidine—Dry mouth—Vandetanib—thyroid cancer	0.00716	0.00716	CcSEcCtD
Apraclonidine—Oedema—Vandetanib—thyroid cancer	0.00702	0.00702	CcSEcCtD
Apraclonidine—Keratitis—Doxorubicin—thyroid cancer	0.007	0.007	CcSEcCtD
Apraclonidine—Parosmia—Doxorubicin—thyroid cancer	0.007	0.007	CcSEcCtD
Apraclonidine—Infection—Vandetanib—thyroid cancer	0.00698	0.00698	CcSEcCtD
Apraclonidine—Nervous system disorder—Vandetanib—thyroid cancer	0.00689	0.00689	CcSEcCtD
Apraclonidine—Skin disorder—Vandetanib—thyroid cancer	0.00682	0.00682	CcSEcCtD
Apraclonidine—Haemorrhage—Sorafenib—thyroid cancer	0.00667	0.00667	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.0064	0.0064	CcSEcCtD
Apraclonidine—Insomnia—Vandetanib—thyroid cancer	0.00635	0.00635	CcSEcCtD
Apraclonidine—Paraesthesia—Vandetanib—thyroid cancer	0.00631	0.00631	CcSEcCtD
Apraclonidine—Dyspnoea—Vandetanib—thyroid cancer	0.00626	0.00626	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00606	0.00606	CcSEcCtD
Apraclonidine—Fatigue—Vandetanib—thyroid cancer	0.00605	0.00605	CcSEcCtD
Apraclonidine—Angiopathy—Sorafenib—thyroid cancer	0.00605	0.00605	CcSEcCtD
Apraclonidine—Mediastinal disorder—Sorafenib—thyroid cancer	0.00601	0.00601	CcSEcCtD
Apraclonidine—Pain—Vandetanib—thyroid cancer	0.006	0.006	CcSEcCtD
Apraclonidine—Constipation—Vandetanib—thyroid cancer	0.006	0.006	CcSEcCtD
Apraclonidine—Arrhythmia—Sorafenib—thyroid cancer	0.00596	0.00596	CcSEcCtD
Apraclonidine—Mental disorder—Sorafenib—thyroid cancer	0.00584	0.00584	CcSEcCtD
Apraclonidine—Erythema—Sorafenib—thyroid cancer	0.0058	0.0058	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00574	0.00574	CcSEcCtD
Apraclonidine—Dysgeusia—Sorafenib—thyroid cancer	0.00568	0.00568	CcSEcCtD
Apraclonidine—Vasodilation procedure—Epirubicin—thyroid cancer	0.00558	0.00558	CcSEcCtD
Apraclonidine—Vasodilation—Epirubicin—thyroid cancer	0.00558	0.00558	CcSEcCtD
Apraclonidine—Abdominal pain—Vandetanib—thyroid cancer	0.00555	0.00555	CcSEcCtD
Apraclonidine—Lacrimation increased—Epirubicin—thyroid cancer	0.00532	0.00532	CcSEcCtD
Apraclonidine—Syncope—Sorafenib—thyroid cancer	0.0052	0.0052	CcSEcCtD
Apraclonidine—Vasodilation—Doxorubicin—thyroid cancer	0.00517	0.00517	CcSEcCtD
Apraclonidine—Vasodilation procedure—Doxorubicin—thyroid cancer	0.00517	0.00517	CcSEcCtD
Apraclonidine—Inflammation—Epirubicin—thyroid cancer	0.00506	0.00506	CcSEcCtD
Apraclonidine—Asthenia—Vandetanib—thyroid cancer	0.00504	0.00504	CcSEcCtD
Apraclonidine—Coordination abnormal—Epirubicin—thyroid cancer	0.005	0.005	CcSEcCtD
Apraclonidine—Pruritus—Vandetanib—thyroid cancer	0.00497	0.00497	CcSEcCtD
Apraclonidine—Myalgia—Sorafenib—thyroid cancer	0.00494	0.00494	CcSEcCtD
Apraclonidine—Lacrimation increased—Doxorubicin—thyroid cancer	0.00493	0.00493	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00491	0.00491	CcSEcCtD
Apraclonidine—Dermatitis contact—Epirubicin—thyroid cancer	0.00485	0.00485	CcSEcCtD
Apraclonidine—Dry mouth—Sorafenib—thyroid cancer	0.00483	0.00483	CcSEcCtD
Apraclonidine—Diarrhoea—Vandetanib—thyroid cancer	0.0048	0.0048	CcSEcCtD
Apraclonidine—Infection—Sorafenib—thyroid cancer	0.00471	0.00471	CcSEcCtD
Apraclonidine—Inflammation—Doxorubicin—thyroid cancer	0.00468	0.00468	CcSEcCtD
Apraclonidine—Nervous system disorder—Sorafenib—thyroid cancer	0.00465	0.00465	CcSEcCtD
Apraclonidine—Dizziness—Vandetanib—thyroid cancer	0.00464	0.00464	CcSEcCtD
Apraclonidine—Coordination abnormal—Doxorubicin—thyroid cancer	0.00462	0.00462	CcSEcCtD
Apraclonidine—Skin disorder—Sorafenib—thyroid cancer	0.0046	0.0046	CcSEcCtD
Apraclonidine—Dry eye—Epirubicin—thyroid cancer	0.00453	0.00453	CcSEcCtD
Apraclonidine—Dermatitis contact—Doxorubicin—thyroid cancer	0.00449	0.00449	CcSEcCtD
Apraclonidine—Vomiting—Vandetanib—thyroid cancer	0.00446	0.00446	CcSEcCtD
Apraclonidine—Dermatitis—Vandetanib—thyroid cancer	0.00442	0.00442	CcSEcCtD
Apraclonidine—Headache—Vandetanib—thyroid cancer	0.0044	0.0044	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00432	0.00432	CcSEcCtD
Apraclonidine—Abnormal vision—Epirubicin—thyroid cancer	0.00428	0.00428	CcSEcCtD
Apraclonidine—Dyspnoea—Sorafenib—thyroid cancer	0.00422	0.00422	CcSEcCtD
Apraclonidine—Dry eye—Doxorubicin—thyroid cancer	0.00419	0.00419	CcSEcCtD
Apraclonidine—Nausea—Vandetanib—thyroid cancer	0.00417	0.00417	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00409	0.00409	CcSEcCtD
Apraclonidine—Fatigue—Sorafenib—thyroid cancer	0.00408	0.00408	CcSEcCtD
Apraclonidine—Pain—Sorafenib—thyroid cancer	0.00405	0.00405	CcSEcCtD
Apraclonidine—Constipation—Sorafenib—thyroid cancer	0.00405	0.00405	CcSEcCtD
Apraclonidine—Abnormal vision—Doxorubicin—thyroid cancer	0.00396	0.00396	CcSEcCtD
Apraclonidine—Eye pain—Epirubicin—thyroid cancer	0.00395	0.00395	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00387	0.00387	CcSEcCtD
Apraclonidine—Abdominal pain—Sorafenib—thyroid cancer	0.00374	0.00374	CcSEcCtD
Apraclonidine—Eye pain—Doxorubicin—thyroid cancer	0.00365	0.00365	CcSEcCtD
Apraclonidine—Hypersensitivity—Sorafenib—thyroid cancer	0.00349	0.00349	CcSEcCtD
Apraclonidine—Face oedema—Epirubicin—thyroid cancer	0.00344	0.00344	CcSEcCtD
Apraclonidine—Asthenia—Sorafenib—thyroid cancer	0.0034	0.0034	CcSEcCtD
Apraclonidine—Pruritus—Sorafenib—thyroid cancer	0.00335	0.00335	CcSEcCtD
Apraclonidine—Diarrhoea—Sorafenib—thyroid cancer	0.00324	0.00324	CcSEcCtD
Apraclonidine—Nasopharyngitis—Epirubicin—thyroid cancer	0.00318	0.00318	CcSEcCtD
Apraclonidine—Face oedema—Doxorubicin—thyroid cancer	0.00318	0.00318	CcSEcCtD
Apraclonidine—Dizziness—Sorafenib—thyroid cancer	0.00313	0.00313	CcSEcCtD
Apraclonidine—Asthma—Epirubicin—thyroid cancer	0.00308	0.00308	CcSEcCtD
Apraclonidine—Vomiting—Sorafenib—thyroid cancer	0.00301	0.00301	CcSEcCtD
Apraclonidine—Dermatitis—Sorafenib—thyroid cancer	0.00298	0.00298	CcSEcCtD
Apraclonidine—Headache—Sorafenib—thyroid cancer	0.00297	0.00297	CcSEcCtD
Apraclonidine—Nasopharyngitis—Doxorubicin—thyroid cancer	0.00295	0.00295	CcSEcCtD
Apraclonidine—Asthma—Doxorubicin—thyroid cancer	0.00285	0.00285	CcSEcCtD
Apraclonidine—Nausea—Sorafenib—thyroid cancer	0.00281	0.00281	CcSEcCtD
Apraclonidine—Infestation NOS—Epirubicin—thyroid cancer	0.00274	0.00274	CcSEcCtD
Apraclonidine—Infestation—Epirubicin—thyroid cancer	0.00274	0.00274	CcSEcCtD
Apraclonidine—Conjunctivitis—Epirubicin—thyroid cancer	0.00267	0.00267	CcSEcCtD
Apraclonidine—Infestation NOS—Doxorubicin—thyroid cancer	0.00254	0.00254	CcSEcCtD
Apraclonidine—Infestation—Doxorubicin—thyroid cancer	0.00254	0.00254	CcSEcCtD
Apraclonidine—Bradycardia—Epirubicin—thyroid cancer	0.00251	0.00251	CcSEcCtD
Apraclonidine—Rhinitis—Epirubicin—thyroid cancer	0.00247	0.00247	CcSEcCtD
Apraclonidine—Conjunctivitis—Doxorubicin—thyroid cancer	0.00247	0.00247	CcSEcCtD
Apraclonidine—Haemorrhage—Epirubicin—thyroid cancer	0.00246	0.00246	CcSEcCtD
Apraclonidine—Pharyngitis—Epirubicin—thyroid cancer	0.00245	0.00245	CcSEcCtD
Apraclonidine—Oedema peripheral—Epirubicin—thyroid cancer	0.00243	0.00243	CcSEcCtD
Apraclonidine—Visual impairment—Epirubicin—thyroid cancer	0.00237	0.00237	CcSEcCtD
Apraclonidine—Bradycardia—Doxorubicin—thyroid cancer	0.00232	0.00232	CcSEcCtD
Apraclonidine—Eye disorder—Epirubicin—thyroid cancer	0.0023	0.0023	CcSEcCtD
Apraclonidine—Rhinitis—Doxorubicin—thyroid cancer	0.00229	0.00229	CcSEcCtD
Apraclonidine—Haemorrhage—Doxorubicin—thyroid cancer	0.00228	0.00228	CcSEcCtD
Apraclonidine—Pharyngitis—Doxorubicin—thyroid cancer	0.00226	0.00226	CcSEcCtD
Apraclonidine—Oedema peripheral—Doxorubicin—thyroid cancer	0.00225	0.00225	CcSEcCtD
Apraclonidine—Angiopathy—Epirubicin—thyroid cancer	0.00224	0.00224	CcSEcCtD
Apraclonidine—Mediastinal disorder—Epirubicin—thyroid cancer	0.00222	0.00222	CcSEcCtD
Apraclonidine—Arrhythmia—Epirubicin—thyroid cancer	0.0022	0.0022	CcSEcCtD
Apraclonidine—Visual impairment—Doxorubicin—thyroid cancer	0.0022	0.0022	CcSEcCtD
Apraclonidine—Mental disorder—Epirubicin—thyroid cancer	0.00216	0.00216	CcSEcCtD
Apraclonidine—Erythema—Epirubicin—thyroid cancer	0.00214	0.00214	CcSEcCtD
Apraclonidine—Eye disorder—Doxorubicin—thyroid cancer	0.00213	0.00213	CcSEcCtD
Apraclonidine—Tension—Epirubicin—thyroid cancer	0.0021	0.0021	CcSEcCtD
Apraclonidine—Dysgeusia—Epirubicin—thyroid cancer	0.0021	0.0021	CcSEcCtD
Apraclonidine—Nervousness—Epirubicin—thyroid cancer	0.00208	0.00208	CcSEcCtD
Apraclonidine—Angiopathy—Doxorubicin—thyroid cancer	0.00207	0.00207	CcSEcCtD
Apraclonidine—Mediastinal disorder—Doxorubicin—thyroid cancer	0.00205	0.00205	CcSEcCtD
Apraclonidine—Arrhythmia—Doxorubicin—thyroid cancer	0.00204	0.00204	CcSEcCtD
Apraclonidine—Vision blurred—Epirubicin—thyroid cancer	0.00202	0.00202	CcSEcCtD
Apraclonidine—Mental disorder—Doxorubicin—thyroid cancer	0.002	0.002	CcSEcCtD
Apraclonidine—Ill-defined disorder—Epirubicin—thyroid cancer	0.00199	0.00199	CcSEcCtD
Apraclonidine—Erythema—Doxorubicin—thyroid cancer	0.00198	0.00198	CcSEcCtD
Apraclonidine—Tension—Doxorubicin—thyroid cancer	0.00195	0.00195	CcSEcCtD
Apraclonidine—Dysgeusia—Doxorubicin—thyroid cancer	0.00194	0.00194	CcSEcCtD
Apraclonidine—Malaise—Epirubicin—thyroid cancer	0.00193	0.00193	CcSEcCtD
Apraclonidine—Nervousness—Doxorubicin—thyroid cancer	0.00193	0.00193	CcSEcCtD
Apraclonidine—Syncope—Epirubicin—thyroid cancer	0.00192	0.00192	CcSEcCtD
Apraclonidine—Palpitations—Epirubicin—thyroid cancer	0.0019	0.0019	CcSEcCtD
Apraclonidine—Vision blurred—Doxorubicin—thyroid cancer	0.00187	0.00187	CcSEcCtD
Apraclonidine—Ill-defined disorder—Doxorubicin—thyroid cancer	0.00184	0.00184	CcSEcCtD
Apraclonidine—Myalgia—Epirubicin—thyroid cancer	0.00183	0.00183	CcSEcCtD
Apraclonidine—Chest pain—Epirubicin—thyroid cancer	0.00183	0.00183	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.00181	0.00181	CcSEcCtD
Apraclonidine—Discomfort—Epirubicin—thyroid cancer	0.0018	0.0018	CcSEcCtD
Apraclonidine—Malaise—Doxorubicin—thyroid cancer	0.00179	0.00179	CcSEcCtD
Apraclonidine—Dry mouth—Epirubicin—thyroid cancer	0.00179	0.00179	CcSEcCtD
Apraclonidine—Syncope—Doxorubicin—thyroid cancer	0.00178	0.00178	CcSEcCtD
Apraclonidine—Palpitations—Doxorubicin—thyroid cancer	0.00175	0.00175	CcSEcCtD
Apraclonidine—Oedema—Epirubicin—thyroid cancer	0.00175	0.00175	CcSEcCtD
Apraclonidine—Infection—Epirubicin—thyroid cancer	0.00174	0.00174	CcSEcCtD
Apraclonidine—Nervous system disorder—Epirubicin—thyroid cancer	0.00172	0.00172	CcSEcCtD
Apraclonidine—Skin disorder—Epirubicin—thyroid cancer	0.0017	0.0017	CcSEcCtD
Apraclonidine—Chest pain—Doxorubicin—thyroid cancer	0.00169	0.00169	CcSEcCtD
Apraclonidine—Myalgia—Doxorubicin—thyroid cancer	0.00169	0.00169	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.00168	0.00168	CcSEcCtD
Apraclonidine—Discomfort—Doxorubicin—thyroid cancer	0.00167	0.00167	CcSEcCtD
Apraclonidine—Dry mouth—Doxorubicin—thyroid cancer	0.00165	0.00165	CcSEcCtD
Apraclonidine—Oedema—Doxorubicin—thyroid cancer	0.00162	0.00162	CcSEcCtD
Apraclonidine—Infection—Doxorubicin—thyroid cancer	0.00161	0.00161	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.00159	0.00159	CcSEcCtD
Apraclonidine—Nervous system disorder—Doxorubicin—thyroid cancer	0.00159	0.00159	CcSEcCtD
Apraclonidine—Insomnia—Epirubicin—thyroid cancer	0.00158	0.00158	CcSEcCtD
Apraclonidine—Skin disorder—Doxorubicin—thyroid cancer	0.00157	0.00157	CcSEcCtD
Apraclonidine—Paraesthesia—Epirubicin—thyroid cancer	0.00157	0.00157	CcSEcCtD
Apraclonidine—Dyspnoea—Epirubicin—thyroid cancer	0.00156	0.00156	CcSEcCtD
Apraclonidine—Somnolence—Epirubicin—thyroid cancer	0.00156	0.00156	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00151	0.00151	CcSEcCtD
Apraclonidine—Fatigue—Epirubicin—thyroid cancer	0.00151	0.00151	CcSEcCtD
Apraclonidine—Constipation—Epirubicin—thyroid cancer	0.0015	0.0015	CcSEcCtD
Apraclonidine—Pain—Epirubicin—thyroid cancer	0.0015	0.0015	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.00148	0.00148	CcSEcCtD
Apraclonidine—Insomnia—Doxorubicin—thyroid cancer	0.00147	0.00147	CcSEcCtD
Apraclonidine—Paraesthesia—Doxorubicin—thyroid cancer	0.00145	0.00145	CcSEcCtD
Apraclonidine—Dyspnoea—Doxorubicin—thyroid cancer	0.00144	0.00144	CcSEcCtD
Apraclonidine—Feeling abnormal—Epirubicin—thyroid cancer	0.00144	0.00144	CcSEcCtD
Apraclonidine—Somnolence—Doxorubicin—thyroid cancer	0.00144	0.00144	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Epirubicin—thyroid cancer	0.00143	0.00143	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.0014	0.0014	CcSEcCtD
Apraclonidine—Fatigue—Doxorubicin—thyroid cancer	0.0014	0.0014	CcSEcCtD
Apraclonidine—Constipation—Doxorubicin—thyroid cancer	0.00139	0.00139	CcSEcCtD
Apraclonidine—Pain—Doxorubicin—thyroid cancer	0.00139	0.00139	CcSEcCtD
Apraclonidine—Abdominal pain—Epirubicin—thyroid cancer	0.00138	0.00138	CcSEcCtD
Apraclonidine—Feeling abnormal—Doxorubicin—thyroid cancer	0.00133	0.00133	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.00132	0.00132	CcSEcCtD
Apraclonidine—Hypersensitivity—Epirubicin—thyroid cancer	0.00129	0.00129	CcSEcCtD
Apraclonidine—Abdominal pain—Doxorubicin—thyroid cancer	0.00128	0.00128	CcSEcCtD
Apraclonidine—Asthenia—Epirubicin—thyroid cancer	0.00126	0.00126	CcSEcCtD
Apraclonidine—Pruritus—Epirubicin—thyroid cancer	0.00124	0.00124	CcSEcCtD
Apraclonidine—Diarrhoea—Epirubicin—thyroid cancer	0.0012	0.0012	CcSEcCtD
Apraclonidine—Hypersensitivity—Doxorubicin—thyroid cancer	0.00119	0.00119	CcSEcCtD
Apraclonidine—Asthenia—Doxorubicin—thyroid cancer	0.00116	0.00116	CcSEcCtD
Apraclonidine—Dizziness—Epirubicin—thyroid cancer	0.00116	0.00116	CcSEcCtD
Apraclonidine—Pruritus—Doxorubicin—thyroid cancer	0.00115	0.00115	CcSEcCtD
Apraclonidine—Vomiting—Epirubicin—thyroid cancer	0.00111	0.00111	CcSEcCtD
Apraclonidine—Diarrhoea—Doxorubicin—thyroid cancer	0.00111	0.00111	CcSEcCtD
Apraclonidine—Dermatitis—Epirubicin—thyroid cancer	0.0011	0.0011	CcSEcCtD
Apraclonidine—Headache—Epirubicin—thyroid cancer	0.0011	0.0011	CcSEcCtD
Apraclonidine—Dizziness—Doxorubicin—thyroid cancer	0.00107	0.00107	CcSEcCtD
Apraclonidine—Nausea—Epirubicin—thyroid cancer	0.00104	0.00104	CcSEcCtD
Apraclonidine—Vomiting—Doxorubicin—thyroid cancer	0.00103	0.00103	CcSEcCtD
Apraclonidine—Dermatitis—Doxorubicin—thyroid cancer	0.00102	0.00102	CcSEcCtD
Apraclonidine—Headache—Doxorubicin—thyroid cancer	0.00101	0.00101	CcSEcCtD
Apraclonidine—Nausea—Doxorubicin—thyroid cancer	0.000962	0.000962	CcSEcCtD
